<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AID</journal-id><journal-title-group><journal-title>Advances in Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-2648</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/aid.2022.122016</article-id><article-id pub-id-type="publisher-id">AID-116985</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Melioidosis an Imported Infection in Qatar: Case Series and Literature Review
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohammed</surname><given-names>Abu Khattab</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohamed</surname><given-names>Abou Kamar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Adham</surname><given-names>Darweesh</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Anand</surname><given-names>Deshmukh</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Infectious Disease Division, Department of Medicine, Hamad General Hospital, Doha, Qatar</addr-line></aff><aff id="aff3"><addr-line>Microbiology Department, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK</addr-line></aff><aff id="aff2"><addr-line>Radiology Department, Hamad General Hospital, Doha, Qatar</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>04</month><year>2022</year></pub-date><volume>12</volume><issue>02</issue><fpage>175</fpage><lpage>192</lpage><history><date date-type="received"><day>24,</day>	<month>March</month>	<year>2022</year></date><date date-type="rev-recd"><day>2,</day>	<month>May</month>	<year>2022</year>	</date><date date-type="accepted"><day>5,</day>	<month>May</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Melioidosis is a tropical infectious disease caused by Gramnegative bacteria 
  <em>Burkholderia pseudomallei (B. pseudomallei)</em>. This soil-borne disease is endemic in Southeast Asia and Northern Australia. In our country it was reported once before in 2000 in a patient who presented with subdural empyema. 
  Case Series Report: We are reporting six cases of Melioidosis presented to our hospital in very close time with different clinical presentations. All patients were from Indian subcontinent. In 3 cases we treated with Meropenem plus Trimethoprim-Sulfamethoxazole (TMP-SMX) followed by oral TMP-SMX and Doxycycline for around 6 months with good clinical and radiological response, while the fourth case was treated with oral TMP-SMX and Doxycycline for 1 month but he lost to follow up, the Fifth cases were treated with IV Ceftazidime followed by TMP-SMX and Doxycycline for 9 weeks, the Sixth cases were treated with IV Ceftazidime followed by TMP-SMX and Amoxicillin/Clavulanic acid for 20 days, there was no mortality reported in our case series for both types Bactraemic and Abactraemic Melioidosis. 
  Conclusions: This case series highlights the importance of early identification of 
  <em>B. pseudomallei</em> which requires a high index of clinical suspicion as well as good understanding of demographical and travel history. Microbiological identification of 
  <em>B. pseudomallei</em> is essential and requires notification of the microbiologist for suspicion of that infection. Prolonged antimicrobial therapy is required for a better clinical outcome.
 
</p></abstract><kwd-group><kwd>Melioidosis</kwd><kwd> Bactraemic</kwd><kwd> Abactraemic Melioidosis</kwd><kwd> &lt;i&gt;Burkholderia pseudomallei&lt;/i&gt;</kwd><kwd> Infection</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Melioidosis is a tropical infectious disease caused by Gram-negative bacteria B. pseudomallei; it is widely distributed in the soil and water within endemic areas.</p><p>B. pseudomallei (the agent of Melioidosis) are related to the genus Burkholderiawhich includes another four species:B. cepacia,B. gladioli,B. pickettii and B. mallei [<xref ref-type="bibr" rid="scirp.116985-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref2">2</xref>].</p><p>It is endemic in certain parts of the world including Southeast Asia and northern Australia [<xref ref-type="bibr" rid="scirp.116985-ref3">3</xref>].</p><p>Recent data indicate that it is now endemic to most of the Indian subcontinent, southern Chinese Mainland, Hong Kong (China), Chinese Taipei, Papua New Guinea, and other regions [<xref ref-type="bibr" rid="scirp.116985-ref4">4</xref>].</p><p>Qatar is a peninsula in Arabian Gulf with estimated population of 2,881,060 million till March 2022, the number of economically active population doubled three times in 14 years (from 444.133 in 2004 to 2.097 million in 2018). This unprecedented growth resulted primarily from the recruitment of large numbers of foreign workers needed for the country’s ambitious development plans. Most of this workforce is from Southeast Asia and Indian subcontinent [<xref ref-type="bibr" rid="scirp.116985-ref5">5</xref>].</p><p>Most cases reported in other regions were acquired during residence in or travel to disease-endemic regions. In our country it was reported once before [<xref ref-type="bibr" rid="scirp.116985-ref6">6</xref>].</p><p>We think that there is no local transmission of the disease, and all cases are imported cases.</p><p>Melioidosis has different presentations including latent infection, local cutaneous lesions, sub-acute pneumonia, focal organ abscess, Musculo-skeletal infection, and lethal fulminant pneumonia [<xref ref-type="bibr" rid="scirp.116985-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref10">10</xref>].</p><p>The disease can cause up to 20% of all community-acquired sepsis in the tropics, including 40% of sepsis-related mortality in Northern Thailand and up to ~20% in the higher-technology setting of Northern Australia [<xref ref-type="bibr" rid="scirp.116985-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref10">10</xref>].</p></sec><sec id="s2"><title>2. First Case</title><p>47-year-old Nepalese male, diabetic not on treatment working in Qatar for 2 years as Gardner with no recent travel history presented to our Accident and Emergency in Hamad Hospital on 23/9/2011 with 10 days history of fever and burning micturition with no other complain.</p><p>On examination patient looks dehydrated, drowsy, and pale temp. 39.7˚C, Bp: 90/60, pulse: 120/min. RR 24 Systemic examination was unremarkable.</p><p>He was started on I.V Piperacillin-Tazobactam 4.5 grams IV every 8 Hours. His initial investigations showed leukocytosis 13.4 &#215; 10<sup>3</sup>/uL, hemoglobin (Hb) 6.5 g/dl (required blood transfusion) with normal coagulation profile, normal renal function test, his liver enzymes where elevated (AST 56 U/L, ALT 49 U/L, ALP 626 U/L).</p><p>Blood cultures were requested, and initial results was showing gram negative bacilli reported later as B. pseudomallei, Antibiotics were changed to IV Meropenem 1-gram Q8 Hrs.; repeated blood culture on 28/9 was persistently positive for B. pseudomallei.</p><p>Ultrasound abdomen was requested which showed multiple hepatic and splenic lesions? Abscess (<xref ref-type="fig" rid="fig1">Figure 1</xref>), ultrasound guided drainage was done on 4/10 draining 70 ml of pus and pig tail catheter was inserted for three days. Repeated blood culture became negative.</p><p>Patient received 15 days of I.V. Meropenem and discharged on 12/10 on oral Trimethoprim-Sulfamethoxazole (TMP-SMX) double strength (DS) 960 mg BID PLUS Doxycycline100 mg PO BID.</p><p>Followed in infectious disease outpatient clinic, repeated ultrasound abdomen on 26/12 showed no collection with complete resolution of the previously describe abscesses (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Antibiotics were stopped a total of 100 days were received; follow up to one year doesn’t show any evidence or recurrence.</p></sec><sec id="s3"><title>3. Second Case</title><p>51-year-old Indian male fisherman living in Qatar for the last 2 years with no recent travel history, known case of chronic carrier of hepatitis B virus with no regular follow up, occasional alcohol consumer, admitted on the 19/12/12 with 10 days history of fever and neck pain, he sought medical attention given oral antibiotics with no improvement.</p><p>On admission he was agitated, confused, febrile temperature was 38.2˚C, blood pressure was 100/60, and his systemic examination apart from neck stiffness was unremarkable.</p><p>He was diagnosed as Meningoencephalitis managed initially with I.V fluids, intravenous Ceftriaxone, Vancomycin and Acyclovir admitted to intensive care unit. Laboratory results where within normal except for elevated liver enzymes ALT 90 U/L AST 194 U/L, high INR of 1.7 and high procalcitonin level 25.14 ng/ml, C-reactive protein 293 mg/l, ESR 58 mm/1hr, lumbar puncture was ordered but could not be done initially due to high INR, but it was done three days later and shows WBC 30 cells, mainly lymphocytes with high protein 5.12 g/l, glucose 3.5 mmol/l.</p><p>Blood cultures were requested on admission and reported as B. pseudomallei; antibiotics changed to Meropenem 1 gram IV Q 8 Hrs. PLUS TMP-SMX 250 mg of trimethoprim component IV Q6 Hrs. according to patient weight.</p><p>Repeated blood cultured were negative, patient improved clinically, but unfortunately while he is on antibiotics, he developed difficulty in walking, with signs of spinal card compression on clinical examination, urgent MRI lumbar spine was requested and showed Para vertebral collection 1.5 cm by 0.75 cm (<xref ref-type="fig" rid="fig3">Figure 3</xref>). CT guided aspiration was done, pus was aspirated culture was negative for bacteria and tuberculosis. Meropenem PLUS TMP-SMX were continued, patient was transferred to rehabilitation unit, he showed good recovery where he was able to walk again without support, repeated MRI showed regression of the Para vertebral collection (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>IV antibiotics were changed to PO Doxycycline plus TMP-SMX. He was treated for total six months. With no recurrence six months after completion of medical treatment.</p></sec><sec id="s4"><title>4. Third Case</title><p>36-year-old Indian male patient living in Qatar for the past 4 year, he was working as fisherman. Newly discovered chronic carrier of hepatitis B virus He presented on 27/1/13 to our hospital with history of fever and right knee pain for the last 15 days, no history of trauma, raw milk ingestion, sexual contact, urinary symptoms, or urethral discharge.</p><p>On examination the right knee was tender, swollen, hot with limitation of movement, no other joint involvement, admitted to surgical floor as right knee septic arthritis, started on IV Ceftriaxone 2 grams IV once daily.</p><p>His blood count and chemistry profile within normal, blood and urine culture where negative, fluid aspirate from the knee shows WBC-11300, mainly neutrophils.</p><p>Patient continued to have fever, MRI of left knee showed early osteomyelitis of lower one third of femur surrounded by tissue swelling and effusion (<xref ref-type="fig" rid="fig5">Figure 5</xref>), underwent incision and drainage of the knee joint multiple times, Synovial fluid and bone tissue culture showed B. pseudomallei.</p><p>Antibiotics were changed to Meropenem 1 gram IV Q 8 Hrs. and TMP-SMX 200 mg of trimethoprim component IV Q12 Hrs. according to patient weight which was given for 9 weeks which was changed to oral TMP-SMX plus Doxycycline upon discharge.</p><p>He was treated for total 5 months with good clinical improvement and no evidence of recurrence on 1 year follow up.</p></sec><sec id="s5"><title>5. Fourth Case</title><p>20-year-old Nepalese male, working in Qatar for 18 months as carpenter, He presented to our hospital on 10/6/12 with history of pus discharge from the right groin for 20 days (<xref ref-type="fig" rid="fig6">Figure 6</xref>), no history of fever, abdominal symptoms, trauma, or sexual contact.</p><p>His complete blood count, chemistry, and liver function within normal and urine, blood cultures where negative, but the swab culture shows B. pseudomallei. Ultrasound groin shows multiple lymph nodes with collection at subcutaneous tissue 7.7 ml of right groin area (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><p>He refused hospital admission, so he was given oral Doxycycline plus TMP-SMX. Follow up Ultrasound showed decrease of the size of the collection to 1 ml (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><p>Patient lost follow up later.</p></sec><sec id="s6"><title>6. Fifth Case</title><p>49 year old Nepalese male patient not known to have any chronic illness before admitted on 19/06/2013 with 10 days history of fever, left hip dull pain. Fever was associated with chills, rigors and fatigue. He had no other complain, no contact with sick patients, no contact with birds or animals Working as Masson in construction, living in Qatar for 5 years with no recent travel history.</p><p>On admission examination was remarkable for fever T 38˚C and palpable spleen 4 cm below costal margin.</p><p>He was started on Piperacillin-Tazobactam and blood cultures were sent. His initial labs showed WBC 4 &#215; 10<sup>3</sup>/uL, Hb 11.4 g/dl, Platelets 147 &#215; 10<sup>3</sup>/uL ALT 35 U/L AST 23 U/L, Na 122 mmol/L creatinine 231 umol/L with high blood sugar 31.4 mmol/l.</p><p>He underwent US abdomen which showed Splenomegaly 14.7 cm. With two heterogeneous to hypoechoic lesions are noted in the spleen with tiny punctate calcifications. The hypoechoic lesions measure 43 &#215; 30 mm and 38 &#215; 30 mm. Punctate calcifications noted throughout the spleen (<xref ref-type="fig" rid="fig9">Figure 9</xref>).</p><p>CT abdomen was done and showed enlarged spleen with multiple hypo dense minimal peripherally enhancing lobulated lesions of variable size are noted in the spleen largest measuring 3.5 &#215; 6.8 cm in the posterior aspect of spleen. There is of rupture of the two of the splenic lesions with mild peri splenic fluid.</p><p>Liver in enlarged in size with two well-defined hypo dense peripherally enhancing lesion measuring 20 &#215; 19 mm and 9 &#215; 8 mm in segment VIII and V respectively. Mild fluid was noted in the right iliac fossa.</p><p>2 days after admission patient deteriorated requiring oxygen transferred to MICU with worsening laboratory results WBC 2.6 &#215; 10<sup>3</sup>/uL, Hb 10.4 g/dl, platelets 77 &#215; 10<sup>3</sup>/uL with evidence of DIC.</p><p>At that time blood culture cam as gram negative bacilli so antibiotics was escalated to Meropenem, general surgery were consulted advised for CT guided aspiration which was done under complete aseptic technique 2 drainage catheters were inserted into the two largest hypodense lesions noted in the spleen. Thick yellowish-greenish pus was aspirated and sent for analysis.</p><p>Patient condition continues to deteriorate intubated and underwent splenectomy.</p><p>Later, blood culture reported as B. pseudomallei sensitive to Meropenem, Ceftazidime and TMP-SMX so patient was changed to Ceftazidime IV after 4 days of Meropenem, the same organism was isolated also from splenic aspirate.</p><p>Patient was investigated further for possibility of disseminated abscesses, so he underwent CT THORAX WITH CONTRAST which showed widespread variable-sized patchy areas of pulmonary consolidation are seen predominantly distributed at the upper lobe. Speculated mass lesion measuring 1.4 &#215; 1 cm is seen at the right middle lobe surrounded by fibrotic changes. Adjacent pulmonary nodules are seen the largest measures 7 mm. Evidence of right sided sub-pulmonic pleural effusion is seen.</p><p>Bilateral mild pleural effusion is seen. Multiple small mediastinal lymph nodes are seen the largest at the right paratracheal region measuring 8 mm in short axis dimension. Subpleural blebs are noted at the apical segment of the right upper lung lobe. In the visualized part of the upper abdomen: focal hypodense lesions are seen in segment VIII and V respectively showing peripheral enhancement representing small liver abscesses.</p><p>Residual free fluid and fat stranding are seen at the surgical bed at the site of splenectomy and adjacent to the posterior stomach wall.</p><p>Left sided perinephric free fluid is noted. Also, small loculated fluid collection at the site of splenectomy measuring approximately 5 &#215; 1 cm.</p><p>He underwent MRI for both thigh with contrast on 03.07.2013: which showed heterogeneous signal intensity in the stairs sequences and T2-weighted images with fat saturation which involving the intramedullary, subcortical area of the head, neck and proximal part of the left femur and adjacent surrounding muscles extending posteriorly involving the posterior lateral part of the left gluteus maximus muscle associated with presence of the none drainable abscess collection intramedullary and within the soft tissue as mentioned above.</p><p>Patient started to improve, and he became afebrile at day 10 of admission, continued IV Ceftazidime for total 6 weeks, then shifted to oral TMP-SMX + amoxicillin/clavulanic acid for another 2 weeks. Discharged home but he lost follow up later.</p></sec><sec id="s7"><title>7. Sixth Case</title><p>53 yrs. Old Bangladeshi male patient known case of DM, HTN, coronary artery disease (CAD), chronic kidney disease (CKD) he was admitted on 18/06/2013 to Heart Hospital with 5 days history of dry cough, bilateral chest pain increased with coughing and intermittent fever. He is in Qatar for 20 years, last travel history to Bangladesh was 3 months back, working as Mosque Imam (religious position).</p><p>His initial examination was unremarkable with normal vital signs. Initial investigations showed leukocytosis 15.1 &#215; 10<sup>3</sup>/uL with normocytic, normochromic anemia with Hb 9.6 g/dl, creatinine 227 umol/L (same as baseline).</p><p>Chest X ray showed Mild increased prominence of the vascular markings noted within both lung zone, blood cultures were sent, and he was started on Ceftriaxone + Azithromycin as case of Community Acquired Pneumonia + Atypical chest pain, blood cultures sent.</p><p>Later, blood cultures came back as B. pseudomallei sensitive to Meropenem, Ceftazidime, TMP-SMX and ciprofloxacin following that he was transferred to medical floor after cardiology clearance and shifted to IV Ceftazidime.</p><p>CT chest showed few areas of fibrotic strands with early bronchiectatic changes noted at the posterior segment of the right upper lobe.</p><p>Patient developed right thigh pain so he was evaluated by US THIGH RT which showed Small well defined hypodense oblong area measuring 1.8 &#215; 0.3 mm is noted in the subcutaneous tissue of the right mid-thigh (at the sight of complain), no evidence of vascularity, likely representing a small subcutaneous collection (<xref ref-type="fig" rid="fig1">Figure 1</xref>0).</p><p>Seen by general surgery with no intervention needed.</p><p>Continued ceftazidime for total 10 days then shifted to Doxycycline + TMP-SMX PO for another 10 days.</p><p>Follow up blood cultures were negative, no follow up thigh Ultrasound.</p><p>Patient was seen in the clinic 1 month after discharge and he was doing well with no further complains.</p><p>Summary of Melioidosis cases reported in Qatar is shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s8"><title>8. Microbiology Identification</title><p>Laboratory identification of B. Pseudomallei can be difficult in our cases all identified by Vitek Compact (bioM&#233;rieux, Marcy l’Etoile, France) and Phoenix (Becton Dickinson, New Jersy and USA). Re-evaluation of the Gram stain and susceptibility pattern was done. The safety pin appearance of the GNB and resistance to Colistin and Gentamycin raised the possibility of B. pseudomallei or B. mallei. The strain was sent to the Mayo Clinic Medical Laboratories (Rochester,</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Summary of Melioidosis cases reported in Qatar</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Age</th><th align="center" valign="middle" >Nationality</th><th align="center" valign="middle" >Occupation</th><th align="center" valign="middle" >Length of stay in Qatar and travel history</th><th align="center" valign="middle" >Risk factors</th><th align="center" valign="middle" >Site of infection</th><th align="center" valign="middle" >Treatment</th><th align="center" valign="middle" >Duration</th><th align="center" valign="middle" >Outcome</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >47 yrs.</td><td align="center" valign="middle" >Nepal</td><td align="center" valign="middle" >Gardner</td><td align="center" valign="middle" >2 years with no recent travel history</td><td align="center" valign="middle" >Diabetes Mellitus (DM)</td><td align="center" valign="middle" >Bacteremia + liver and splenic abscesses</td><td align="center" valign="middle" >Iv Meropenem</td><td align="center" valign="middle" >3 months and 10 days</td><td align="center" valign="middle" >Cured</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >51 yrs.</td><td align="center" valign="middle" >India</td><td align="center" valign="middle" >Fisherman</td><td align="center" valign="middle" >2 years with no recent travel history</td><td align="center" valign="middle" >Chronic hepatitis B + alcohol consumption + DM</td><td align="center" valign="middle" >Bacteremia + vertebral osteomyelitis + paraspinal abscess</td><td align="center" valign="middle" >Iv Meropenem + TMP-SMX Followed by Doxycycline + TMP-SMX</td><td align="center" valign="middle" >6 months</td><td align="center" valign="middle" >Cured</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >36 yrs.</td><td align="center" valign="middle" >India</td><td align="center" valign="middle" >Fisherman</td><td align="center" valign="middle" >4 year with no recent travel history</td><td align="center" valign="middle" >Chronic hepatitis B, No History of Diabetes Mellitus</td><td align="center" valign="middle" >Knee septic arthritis + osteomyelitis</td><td align="center" valign="middle" >Iv Meropenem + TMP-SMX Followed by Doxycycline + TMP-SMX</td><td align="center" valign="middle" >6 months</td><td align="center" valign="middle" >Cured</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >20 yrs.</td><td align="center" valign="middle" >Nepal</td><td align="center" valign="middle" >Carpenter</td><td align="center" valign="middle" >18 months with no recent travel history</td><td align="center" valign="middle" >No risk factors</td><td align="center" valign="middle" >Groin sinus</td><td align="center" valign="middle" >Doxycycline + TMP-SMX PO</td><td align="center" valign="middle" >1 month</td><td align="center" valign="middle" >Lost follow up</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >49 yrs.</td><td align="center" valign="middle" >Nepal</td><td align="center" valign="middle" >Masson</td><td align="center" valign="middle" >5 years with no recent travel history</td><td align="center" valign="middle" >DM</td><td align="center" valign="middle" >Bacteremia + liver and splenic abscesses + thigh abscess</td><td align="center" valign="middle" >Iv Meropenem then Ceftazidime Followed by Amoxi/ clav +TMP-SMX</td><td align="center" valign="middle" >9 weeks</td><td align="center" valign="middle" >Lost follow up</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >53 yrs.</td><td align="center" valign="middle" >Bangladeshi</td><td align="center" valign="middle" >Mosque Imam</td><td align="center" valign="middle" >20 years with recent travel history 3 months prior to presentation</td><td align="center" valign="middle" >DM, HTN, CAD, CKD</td><td align="center" valign="middle" >Bacteremia + thigh abscess</td><td align="center" valign="middle" >Iv Ceftazidime Followed by Doxycycline + TMP-SMX</td><td align="center" valign="middle" >20 days</td><td align="center" valign="middle" >Cured</td></tr><tr><td align="center" valign="middle" >7 (Faraj S. et al.)</td><td align="center" valign="middle" >45 yrs.</td><td align="center" valign="middle" >Unknown</td><td align="center" valign="middle" >Unknown</td><td align="center" valign="middle" >Returned from India few days prior to presentation</td><td align="center" valign="middle" >DM</td><td align="center" valign="middle" >bacteremia + Disseminated infection</td><td align="center" valign="middle" >Ceftazidime + TMP-SMX followed by cefuroxime + TMP-SMX</td><td align="center" valign="middle" >6 months</td><td align="center" valign="middle" >Cured</td></tr></tbody></table></table-wrap><p>USA) which identified the organism as B. pseudomallei 16S RNA sequencing. 2 strains genetic sequencing shows that they are different strains.</p></sec><sec id="s9"><title>9. Discussion</title><p>B. pseudomallei and its role in human disease were first described by Whitmore and Krishnaswami in 1912 [<xref ref-type="bibr" rid="scirp.116985-ref11">11</xref>]. Transmission of infection can occur through skin, lungs (inhalation, aspiration) and occasionally by ingestion. Inhalation thought to be the most common route of acquisition of B. pseudomallei by different case reported in the literature [<xref ref-type="bibr" rid="scirp.116985-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref13">13</xref>].</p><p>But now percutaneous inoculation during exposure to wet season soils or contaminated water is considered the predominant mode of transmission [<xref ref-type="bibr" rid="scirp.116985-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref16">16</xref>]. Cases of pneumonia following skin injuries are well documented, suggesting that the organism can reach the lungs via the hematogenous route [<xref ref-type="bibr" rid="scirp.116985-ref15">15</xref>].</p><p>Person-to-person transmission is extremely unusual, despite the large bacterial load in severely ill patients with Septicemic pulmonary Melioidosis [<xref ref-type="bibr" rid="scirp.116985-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref18">18</xref>]. Transmission from Mother to infant can happen during breastfeeding especially in the setting of B. pseudomallei mastitis [<xref ref-type="bibr" rid="scirp.116985-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref19">19</xref>]. Laboratory-acquired infections and iatrogenic infections from contaminated hospital or surgical equipment occasionally occur [<xref ref-type="bibr" rid="scirp.116985-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref21">21</xref>].</p><p>Transmission related to animal exposure is very rare; three possible cases have been described in Australia [<xref ref-type="bibr" rid="scirp.116985-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref23">23</xref>]. Ingestion of water also postulated as uncommon routes of transmission. However, a study from Thailand raised the possibility that ingestion of water contaminated with B. pseudomallei may be a more common source of infection than previously thought, especially in endemic regions with unchlorinated water supplies [<xref ref-type="bibr" rid="scirp.116985-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref26">26</xref>]. Sexual transmission is uncommon [<xref ref-type="bibr" rid="scirp.116985-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref28">28</xref>].</p><p>The most important risk factors for Melioidosis are diabetes, hazardous alcohol use, and chronic renal disease [<xref ref-type="bibr" rid="scirp.116985-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref32">32</xref>]. Other risk factors include chronic lung disease (present in 27 percent of cases in the Northern Territory Study) [<xref ref-type="bibr" rid="scirp.116985-ref33">33</xref>], thalassemia [<xref ref-type="bibr" rid="scirp.116985-ref31">31</xref>], and kava consumption [<xref ref-type="bibr" rid="scirp.116985-ref15">15</xref>] (The roots of the plant are used to produce a drink with sedative and anesthetic properties. Kava is consumed throughout the Pacific Ocean cultures of Polynesia, including Hawaii, Vanuatu, Melanesia, and some parts of Micronesia). Malignancy, steroid and other immunosuppressive therapy, rheumatic heart disease and/or congestive cardiac failure [<xref ref-type="bibr" rid="scirp.116985-ref30">30</xref>]. Pulmonary hemosiderosis [<xref ref-type="bibr" rid="scirp.116985-ref34">34</xref>], chronic granulomatous disease [<xref ref-type="bibr" rid="scirp.116985-ref35">35</xref>], and tuberculosis are probable risk factors, but are not yet confirmed to be independent risk factors [<xref ref-type="bibr" rid="scirp.116985-ref31">31</xref>].</p><p>In our case series risk factors, which could be found Diabetes in 4 patients and chronic Hepatitis b infection in 2 patient one of them was also diabetic and alcohol consumer, one patient was healthy with no risk factors. Hepatitis B as a risk factor for Melioidosis was not previously described in the literature and presence of that relations need to be subjected to further studies.</p><p>Melioidosis can be classify to Acute disease is defined as symptoms lasting for less than two months. Chronic disease is defined as symptoms persisting for longer than two months [<xref ref-type="bibr" rid="scirp.116985-ref36">36</xref>]. The incubation period following inoculating injury ranges from 1 to 21 days (mean nine days) [<xref ref-type="bibr" rid="scirp.116985-ref36">36</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref37">37</xref>] and it can be as long as 26 years [<xref ref-type="bibr" rid="scirp.116985-ref38">38</xref>], depending on the inoculating dose, virulence properties of the isolate, mode of transmission, and host risk factors [<xref ref-type="bibr" rid="scirp.116985-ref39">39</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref40">40</xref>]. Melioidosis is not endemic disease in Qatar, all our cases are expatriates but since they had no recent travel history except for the last case we think that they were incubating the disease prior to arrival to Qatar with relatively long incubation period.</p><p>Clinical presentation of Melioidosis can be variable but the most common manifestations are pneumonitis, lung abscess, soft-tissue infection, osteomyelitis, lymphadenitis, splenic abscess, liver abscess, and septicemia. As shown in our case series that bactraemic type with deep abscess formation is the most common presentation 75% of cases reported from Qatar (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Treatment of Melioidosis, even mild disease, should be with initial intensive therapy (at least 2 weeks of intravenous therapy) followed by eradication therapy orally for a minimum of three months. Initial intensive therapy with one of the following regimens Ceftazidime, Meropenem, Imipenem [<xref ref-type="bibr" rid="scirp.116985-ref41">41</xref>]. Trimethoprim-Sulfamethoxazole (TMP-SMX) may be added to other antibiotics aiming to decrease antibiotics resistance in specific clinical presentations such as neurologic, prostatic, bone, joint, cutaneous, and soft tissue Melioidosis [<xref ref-type="bibr" rid="scirp.116985-ref42">42</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref43">43</xref>]. Further studies fail to show benefit from addition of trimethoprim-sulfamethoxazole in form of decreasing mortality or culture-confirmed recurrent Melioidosis [<xref ref-type="bibr" rid="scirp.116985-ref44">44</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref45">45</xref>].</p><p>In eradication therapy Trimethoprim-Sulfamethoxazole is the drug of choice, combination of Doxycycline plus TMP-SMX was evaluated and studies does not show difference in the rates of recurrence of Melioidosis but, a higher rate of adverse drug reactions were noticed when Doxycycline was added to regimen [<xref ref-type="bibr" rid="scirp.116985-ref46">46</xref>].</p><p>Other drugs were evaluated for treatment of Melioidosis like Amoxicillin-Clavulanate alone and oral Quinolones alone or in combination with Azithromycin and found to be less effective in preventing relapse than eradication therapy with TMP-SMX and Doxycycline with or without Chloramphenicol [<xref ref-type="bibr" rid="scirp.116985-ref47">47</xref>] - [<xref ref-type="bibr" rid="scirp.116985-ref53">53</xref>].</p><p>All our patients were treated initially with either Ceftazidime or Meropenem followed by oral antibiotics including Doxycycline/TMP-SMX for 3 - 6 months except for one patient who lost his follow up.</p><p>3 of our patients who were treated with combination therapy 1 treated with monotherapy and 2 treated with monotherapy followed by combination therapy showed good clinical response and drugs were well tolerated which may suggest that patients may get benefit from combination therapy but of course our number of patients was small and bigger studies are needed to evaluate this issue. Relapse after apparent cure of has been reported and may reach up to 15% per year of follow-up [<xref ref-type="bibr" rid="scirp.116985-ref41">41</xref>]. In our cases no relapse was documented with follow up 6 - 12 months.</p></sec><sec id="s10"><title>10. Conclusions</title><p>Melioidosis, although rare in this geographic region, should be considered in the differential diagnosis for ill residents or travelers from areas of endemicity. Confirmed human sporadic cases in the Middle East have been reported in Iran, and suspected cases in Egypt, the United Arab Emirates and Saudi Arabia has been reported but not confirmed [<xref ref-type="bibr" rid="scirp.116985-ref54">54</xref>] and one confirmed case in Qatar, Cases in animals have also been reported from Iran, Saudi Arabia and Oman [<xref ref-type="bibr" rid="scirp.116985-ref55">55</xref>] [<xref ref-type="bibr" rid="scirp.116985-ref56">56</xref>].</p><p>All our reported cases are from expatriates namely from India and Nepal we believe that those cases are imported but further evidence for the existence of B. pseudomallei as epizootic or in soil is lacking in our region and further studies are needed. We are reporting series of confirmed cases diagnosed in Qatar in very close period and this is considered the first confirmed series of cases in humans diagnosed in our region, we could not find a clear link between those cases neither in demographic characteristics nor in genetic sequencing for two of those cases. Our cases had different clinical presentations ranging from mild infection to severe Septicemic type all treated medically with appropriate surgical intervention when needed with good outcome and no mortality recorded in our cases. Two of our cases were found to be chronic carriers of hepatitis B infection and we think that further studies are needed to determine if it could be a significant risk factor for the disease.</p></sec><sec id="s11"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s12"><title>Cite this paper</title><p>Abu Khattab, M., Abou Kamar, M., Darweesh, A. and Deshmukh, A. (2022) Melioidosis an Imported Infection in Qatar: Case Series and Literature Review. Advances in Infectious Diseases, 12, 175-192. https://doi.org/10.4236/aid.2022.122016</p></sec></body><back><ref-list><title>References</title><ref id="scirp.116985-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Phillips, I., Eykyn, S. and Laker, M. (1972) Outbreak of Hospital Infection Caused by Contaminated Autoclaved Fluids. Lancet, 1, 1258-1260. https://doi.org/10.1016/S0140-6736(72)90981-6</mixed-citation></ref><ref id="scirp.116985-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Howe, C. and Miller, W.R. (1947) Human Glanders: Report of Six Cases. Annals of Internal Medicine, 26, 93-115. https://doi.org/10.7326/0003-4819-26-1-93</mixed-citation></ref><ref id="scirp.116985-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">White NJ (2003) Melioidosis. Lancet, 361, 1715-1722. https://doi.org/10.1016/S0140-6736(03)13374-0</mixed-citation></ref><ref id="scirp.116985-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Currie, B.J., Dance, D.A. and Cheng, A.C. (2008) The Global Distribution of Burkholderia pseudomallei and Melioidosis: An Update. Transactions of the Royal Society of Tropical Medicine and Hygiene, 102, S1-S4. https://doi.org/10.1016/S0035-9203(08)70002-6</mixed-citation></ref><ref id="scirp.116985-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Qatar Statistics Authority. https://www.psa.gov.qa/en/pages/default.aspx</mixed-citation></ref><ref id="scirp.116985-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Al Alousi, F.S., Al Soub, H. and El-Shafie, S.S. (2000) Subdural Empyema Due to Burkholderia pseudomallei. Annals of Saudi Medicine, 20, 272-273. https://doi.org/10.5144/0256-4947.2000.272</mixed-citation></ref><ref id="scirp.116985-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wiersinga, W.J., van der Poll, T., White, N.J., Day, N.P. and Peacock, S.J. (2006) Melioidosis: Insights into the Pathogenicity of Burkholderia pseudomallei. Nature Reviews Microbiology, 4, 272-282. https://doi.org/10.1038/nrmicro1385</mixed-citation></ref><ref id="scirp.116985-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Inglis, T.J., Rolim, D.B. and Sousa Ade, Q. (2006) Melioidosis in the Americas. The American Journal of Tropical Medicine and Hygiene, 75, 947-954. https://doi.org/10.4269/ajtmh.2006.75.947</mixed-citation></ref><ref id="scirp.116985-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Currie, B.J., Haslem, A., Pearson, T., Hornstra, H., Leadem, B., Mayo, M., Gal D., Ward, L., Godoy, D., Spratt, B.G., et al. (2009) Identification of Melioidosis Outbreak by Multi Locus Variable Number Tandem Repeat Analysis. Emerging Infectious Diseases, 15, 169-174. https://doi.org/10.3201/eid1502.081036</mixed-citation></ref><ref id="scirp.116985-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, A.C. and Currie, B.J. (2005) Melioidosis: Epidemiology, Pathophysiology, and Management. Clinical Microbiology Reviews, 18, 383-416. https://doi.org/10.1128/CMR.18.2.383-416.2005</mixed-citation></ref><ref id="scirp.116985-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Whitmore, A. and Krishnaswami, C.S. (1912) An Account of the Discovery of a Hitherto Undescribed Infective Disease Occurring among the Population of Rangoon. Indian Medical Gazette, 47, 262-267.</mixed-citation></ref><ref id="scirp.116985-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Brundage, W.G., Thuss Jr., C.J. and Walden, D.C. (1968) Four Fatal Cases of Melioidosis in US Soldiers in Vietnam. Bacteriologic and Pathologic Characteristics. The American Journal of Tropical Medicine and Hygiene, 17, 183-191. https://doi.org/10.4269/ajtmh.1968.17.183</mixed-citation></ref><ref id="scirp.116985-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mackowiak, P.A. and Smith, J.W. (1978) Septicemic Melioidosis Occurrence Following Acute Influenza a Six Years after Exposure in Vietnam. JAMA, 240, 764-766. https://doi.org/10.1001/jama.1978.03290080054027</mixed-citation></ref><ref id="scirp.116985-ref14"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dance</surname><given-names> D.B. </given-names></name>,<etal>et al</etal>. (<year>1990</year>)<article-title>Melioidosis</article-title><source> Reviews in Medical Microbiology</source><volume> 1</volume>,<fpage> 143</fpage>-<lpage>150</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.116985-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Currie, B.J., Fisher, D.A., Howard, D.M., Burrow, J.N., Selvanayagam, S., Snelling, P.L., Anstey, N.M. and Mayo, M.J. (2000) The Epidemiology of Melioidosis in Australia and Papua New Guinea. Acta Tropica, 74, 121-127. https://doi.org/10.1016/S0001-706X(99)00060-1</mixed-citation></ref><ref id="scirp.116985-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Leelarasamee, A. and Bovornkitti, S. (1989) Melioidosis: Review and Update. Reviews of Infectious Diseases, 11, 413-425. https://doi.org/10.1093/clinids/11.3.413</mixed-citation></ref><ref id="scirp.116985-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Dance, D.A. (2000) Ecology of Burkholderia pseudomallei and the Interactions between Environmental Burkholderia spp. and Human-Animal Hosts. Acta Tropica, 74, 159-168. https://doi.org/10.1016/S0001-706X(99)00066-2</mixed-citation></ref><ref id="scirp.116985-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kunakorn, M., Jayanetra, P. and Tanphaichitra, D (1991) Man-to-Man Transmission of Melioidosis. Lancet, 337, 1290-1291. https://doi.org/10.1016/0140-6736(91)92962-2</mixed-citation></ref><ref id="scirp.116985-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ralph, A., McBride, J. and Currie, B.J. (2004) Transmission of Burkholderia pseudomallei via Breast Milk in Northern Australia. The Pediatric Infectious Disease Journal, 23, 1169-1171.</mixed-citation></ref><ref id="scirp.116985-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Green, R.N. and Tuffnell, P.G. (1968) Laboratory Acquired Melioidosis. The American Journal of Medicine, 44, 599-605. https://doi.org/10.1016/0002-9343(68)90060-0</mixed-citation></ref><ref id="scirp.116985-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ashdown, L.R. (1979) Nosocomial Infection Due to Pseudomonas pseudomallei: Two Cases and an Epidemiologic Study. Reviews of Infectious Diseases, 1, 891-694. https://doi.org/10.1093/clinids/1.5.891</mixed-citation></ref><ref id="scirp.116985-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Choy, J.L., Mayo, M., Janmaat, A. and Currie, B.J. (2000) Animal Melioidosis in Australia. Acta Tropica, 74, 153-158. https://doi.org/10.1016/S0001-706X(99)00065-0</mixed-citation></ref><ref id="scirp.116985-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Stanton, A.T. and Fletcher, W. (1932) Melioidosis. Vol. 21, John Bale and Danielson Ltd., London.</mixed-citation></ref><ref id="scirp.116985-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Cottew, G.S., Sutherland, A.K. and Meehan, J.F. (1952) Melioidosis in Sheep in Queensland. Australian Veterinary Journal, 28, 113-123.</mixed-citation></ref><ref id="scirp.116985-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ketterer, P.J., Webster, W.R., Shield, J., Arthur, R.J., Blackall, P.J. and Thomas, A.D. (1986) Melioidosis in Intensive Piggeries in Southeastern Queensland. Australian Veterinary Journal, 63, 146-149. https://doi.org/10.1111/j.1751-0813.1986.tb02953.x</mixed-citation></ref><ref id="scirp.116985-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Limmathurotsakul, D., Kanoksil, M., Wuthiekanun, V., Kitphati, R., de Stavola, B., Day, N.P. and Peacock, S.J. (2013) Activities of Daily Living Associated with Acquisition of Melioidosis in Northeast Thailand: A Matched Case-Control Study. PLoS Neglected Tropical Diseases, 7, Article No. e2072. https://doi.org/10.1371/journal.pntd.0002072</mixed-citation></ref><ref id="scirp.116985-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">McCormick, J.B., Sexton, D.J., McMurray, J.G., Carey, E., Hayes, P. and Feldman, R.A. (1975) Human-to-Human Transmission of Pseudomonas pseudomallei. Annals of Internal Medicine, 83, 512-513. https://doi.org/10.7326/0003-4819-83-4-512</mixed-citation></ref><ref id="scirp.116985-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Webling, D.D. (1980) Genito-Urinary Infections with Pseudomonas pseudomallei in Australian Aboriginals. Transactions of the Royal Society of Tropical Medicine and Hygiene, 74, 138-139. https://doi.org/10.1016/0035-9203(80)90036-X</mixed-citation></ref><ref id="scirp.116985-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Chaowagul, W., White, N.J., Dance, D.A., Wattanagoon, Y., Naigowit, P., Davis, T.M., Looareesuwan, S. and Pitakwatchara, N. (1989) Melioidosis: A Major Cause of Community-Acquired Septicemia in Northeastern Thailand. The Journal of Infectious Diseases, 159, 890-899. https://doi.org/10.1093/infdis/159.5.890</mixed-citation></ref><ref id="scirp.116985-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Currie, B.J., Ward, L. and Cheng, A.C. (2010) The Epidemiology and Clinical Spectrum of Melioidosis: 540 Cases from the 20 Year Darwin Prospective Study. PLoS Neglected Tropical Diseases, 4, Article No. e900. https://doi.org/10.1371/journal.pntd.0000900</mixed-citation></ref><ref id="scirp.116985-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Suputtamongkol, Y., Chaowagul, W., Chetchotisakd, P., Lertpatanasuwun, N., Intaranongpai, S., Ruchutrakool, T., Budhsarawong, D., Mootsikapun, P., Wuthiekanun, V., Teerawatasook, N. and Lulitanond, A. (1999) Risk Factors for Melioidosis and Bactraemic Melioidosis. Clinical Infectious Diseases, 29, 408-413. https://doi.org/10.1086/520223</mixed-citation></ref><ref id="scirp.116985-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Currie, B.J., Jacups, S.P., Cheng, A.C., Fisher, D.A., Anstey, N.M., Huffam, S.E. and Krause, V.L. (2004) Melioidosis Epidemiology and Risk Factors from a Prospective Whole-Population Study in Northern Australia. Tropical Medicine &amp; International Health, 9, 1167-1174. https://doi.org/10.1111/j.1365-3156.2004.01328.x</mixed-citation></ref><ref id="scirp.116985-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Currie, B.J., Fisher, D.A., Howard, D.M., Burrow, J.N., Lo, D., Selva-Nayagam, S., Anstey, N.M., Huffam, S.E., Snelling, P.L., Marks, P.J., Stephens, D.P., Lum, G.D., Jacups, S.P. and Krause, V.L. (2000) Endemic Melioidosis in Tropical Northern Australia: A 10-Year Prospective Study and Review of the Literature. Clinical Infectious Diseases, 31, 981-986. https://doi.org/10.1086/318116</mixed-citation></ref><ref id="scirp.116985-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Ruchin, P., Robinson, J., Segasothy, M. and Morey, F. (2000) Melioidosis in a Patient with Idiopathic Pulmonary Hemosiderosis Resident in Central Australia. Australian and New Zealand Journal of Medicine, 30, 395-396. https://doi.org/10.1111/j.1445-5994.2000.tb00844.x</mixed-citation></ref><ref id="scirp.116985-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Tarlow, M.J. and Lloyd, J. (1971) Melioidosis and Chronic Granulomatous Disease. Journal of the Royal Society of Medicine, 64, 19-20. https://doi.org/10.1177/003591577106400111</mixed-citation></ref><ref id="scirp.116985-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Currie, B.J., Fisher, D.A., Anstey, N.M. and Jacups, S.P. (2000) Melioidosis: Acute and Chronic Disease, Relapse and Re-Activation. Transactions of The Royal Society of Tropical Medicine and Hygiene, 94, 301-304. https://doi.org/10.1016/S0035-9203(00)90333-X</mixed-citation></ref><ref id="scirp.116985-ref37"><label>37</label><mixed-citation publication-type="book" xlink:type="simple">Sookpranee, M., Lumbiganon, P. and Boonma, P. (1989) Nosocomial Contamination of Pseudomonas pseudomallei in the Patients at Srinagarind Hospital. In: Punyagupta, S., Sirisanthana, T. and Stapatayavong, B., Eds., Melioidosis, Bangkok Medical Publisher, Bangkok.</mixed-citation></ref><ref id="scirp.116985-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Mays, E.E. and Ricketts, E.A. (1975) Melioidosis: Recrudescence Associated with Bronchogenic Carcinoma Twenty-Six Years Following Initial Geographic Exposure. Chest, 68, 261-263. https://doi.org/10.1378/chest.68.2.261</mixed-citation></ref><ref id="scirp.116985-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Howe, C., Sampath, A. and Spotnitz, M. (1971) The Pseudomallei Group: A Review. The Journal of Infectious Diseases, 124, 598-606. https://doi.org/10.1093/infdis/124.6.598</mixed-citation></ref><ref id="scirp.116985-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Bovornkitti, S., Leelarasamee, A. and Thamlikitkul, V. (1985) Melioidosis. Monaldi Archives, 40, 203-210.</mixed-citation></ref><ref id="scirp.116985-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Smith, M.D., Wuthiekanun, V., Walsh, A.L. and White, N.J. (1994) Susceptibility of Pseudomonas pseudomallei to Some Newer Beta-Lactam Antibiotics and Antibiotic Combinations Using Time-Kill Studies. Journal of Antimicrobial Chemotherapy, 33, 145-149. https://doi.org/10.1093/jac/33.1.145</mixed-citation></ref><ref id="scirp.116985-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, A.C., McBryde, E.S., Wuthiekanun, V., Chierakul, W., Amornchai, P., Day, N.P., White, N.J. and Peacock, S.J. (2009) Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis. Antimicrobial Agents and Chemotherapy, 53, 4193-4199. https://doi.org/10.1128/AAC.01301-08</mixed-citation></ref><ref id="scirp.116985-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Chetchotisakd, P., Chierakul, W., Chaowagul, W., Anunnatsiri, S., Phimda, K., Mootsikapun, P., Chaisuksant, S., Pilaikul, J., Thinkhamrop, B., Phiphitaporn, S., Susaengrat, W., Toondee, C., Wongrattanacheewin, S., Wuthiekanun, V., Chantratita, N., Thaipadungpanit, J., Day, N.P., Limmathurotsakul, D. and Peacock, S.J. (2014) Trimethoprim-Sulfamethaxazole versus Trimethoprim-Sulfamethaxazole Plus Doxycycline as Oral Eradicative Treatment for Melioidosis (MERTH): A Multicenter, Double-Blind, Non-Inferiority, Randomized Controlled Trial. Lancet, 383, 807-814. https://doi.org/10.1016/S0140-6736(13)61951-0</mixed-citation></ref><ref id="scirp.116985-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Chierakul, W., Anunnatsiri, S., Short, J.M., Maharjan, B., Mootsikapun, P., Simpson, A.J., Limmathurotsakul, D., Cheng, A.C., Stepniewska, K., Newton, P.N., Chaowagul, W., White, N.J., Peacock, S.J., Day, N.P. and Chetchotisakd, P. (2005) Two Randomized Controlled Trials of Ceftazidime alone versus Ceftazidime in Combination with Trimethoprim-Sulfamethoxazole for the Treatment of Severe Melioidosis. Clinical Infectious Diseases, 41, 1105-1113. https://doi.org/10.1086/444456</mixed-citation></ref><ref id="scirp.116985-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Chierakul, W., Anunnatsiri, S., Chaowagul, W., Peacock, S.J., Chetchotisakd, P. and Day, N.P. (2007) Addition of Trimethoprim-Sulfamethoxazole to Ceftazidime during Parenteral Treatment of Melioidosis Is Not Associated with a Long-Term Outcome Benefit. Clinical Infectious Diseases, 45, 521-523. https://doi.org/10.1086/520010</mixed-citation></ref><ref id="scirp.116985-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Currie, B.J. (2003) Melioidosis: An Important Cause of Pneumonia in Residents of and Travelers Returned from Endemic Regions. European Respiratory Journal, 22, 542. https://doi.org/10.1183/09031936.03.00006203</mixed-citation></ref><ref id="scirp.116985-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Chaowagul W. (2000) Recent Advances in the Treatment of Severe Melioidosis. Acta Tropica, 74, 133-137. https://doi.org/10.1016/S0001-706X(99)00062-5</mixed-citation></ref><ref id="scirp.116985-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Rajchanuvong A, Chaowagul W, Suputtamongkol Y, Smith MD, Dance DA, White NJ. (1995) A Prospective Comparison of Co-Amoxiclav and the Combination of Chloramphenicol, Doxycycline, and Co-Trimoxazole for the Oral Maintenance Treatment of Melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 546-549. https://doi.org/10.1016/0035-9203(95)90104-3</mixed-citation></ref><ref id="scirp.116985-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Chaowagul, W., Suputtamongkul, Y., Smith, M.D. and White, N.J. (1997) Oral Fluoroquinolones for Maintenance Treatment of Melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91, 599-601. https://doi.org/10.1016/S0035-9203(97)90044-4</mixed-citation></ref><ref id="scirp.116985-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Chetchotisakd, P., Chaowagul, W., Mootsikapun, P., Budhsarawong, D., Thinkamrop, B. (2001) Maintenance Therapy of Melioidosis with Ciprofloxacin plus Azithromycin Compared with Cotrimoxazole plus Doxycycline. The American Journal of Tropical Medicine and Hygiene, 64, 24-27. https://doi.org/10.4269/ajtmh.2001.64.24</mixed-citation></ref><ref id="scirp.116985-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Ashdown, L.R. and Currie, B.J. (1992) Melioidosis: When in Doubt Leave the Quinolone alone! Medical Journal of Australia, 157, 427-428. https://doi.org/10.5694/j.1326-5377.1992.tb137276.x</mixed-citation></ref><ref id="scirp.116985-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Gilad, J., Harary, I., Dushnitsky, T., Schwartz, D. and Amsalem, Y. (2007, July 9) Burkholderia mallei and Burkholderia pseudomallei as Bioterrorism Agents: National Aspects of Emergency Preparedness. The Israel Medical Association Journal, 9, 499-503.</mixed-citation></ref><ref id="scirp.116985-ref53"><label>53</label><mixed-citation publication-type="book" xlink:type="simple">Sprague, L.D. and Elschner, M.C. (2012) Burkholderia pseudomallei: Melioidosis. In: Elschner, M.C., Cutler, S.J., Weidmann, M. and Butaye, P., Eds., BSL3 and BSL4 Agents: Epidemiology, Microbiology, and Practical Guidelines, Wiley-VCH Verlag GmbH &amp; Co. KGaA, Hoboken, 47-56. https://doi.org/10.1002/9783527645114.ch4</mixed-citation></ref><ref id="scirp.116985-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Pourtaghva, M, Dodin, A, Portovi, M, Teherani, M. and Galimand, M. (1977) 1st Case of Human Pulmonary Melioidosis in Iran. Bulletin de la Société de Pathologie Exotique, 70, 107-109.</mixed-citation></ref><ref id="scirp.116985-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Almarhabi, H., Munshi, A., Althobaiti, M., et al. (2022, February 3) Melioidosis Pneumonia in Saudi Arabia: A Rare Case Report and Review of the Literature. Cureus, 14, Article ID: e21871. https://doi.org/10.7759/cureus.21871</mixed-citation></ref><ref id="scirp.116985-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Al Tamtami, N., Khamis, F. and Al-Jardani, A. (2017) Imported Case of Melioidosis in Oman: Case Report. Oman Medical Journal, 32, 62-65. https://doi.org/10.5001/omj.2017.11</mixed-citation></ref></ref-list></back></article>